심근경색(MI) 치료제 시장 : 시장 규모, 점유율, 성장 분석 - 치료 유형별, 약제 클래스별, 투여 경로별, 최종 사용자별, 지역별 - 산업예측(2025-2032년)
Myocardial Infarction Therapeutics Market Size, Share, Growth Analysis, By Therapy Type (Thrombolysis, Primary Percutaneous Coronary Intervention ), By Drug Class, By Route of Administration, By End-User, By Region - Industry Forecast 2025-2032
상품코드:1623942
리서치사:SkyQuest
발행일:2025년 01월
페이지 정보:영문 257 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 심근경색(MI) 치료제 시장 규모는 2023년 217억 5,000만 달러로 평가되었고, 2024년 227억 3,000만 달러에서 2032년에는 323억 2,000만 달러로 성장할 전망이며, 예측기간 2025년부터 2032년까지의 CAGR은 4.5%로 성장할 전망입니다.
심근경색(MI) 치료제 시장은 심장발작의 주요 원인인 관상동맥질환의 이환율 상승을 주요 요인으로 하여 큰 성장이 예상되고 있습니다. 연간 약 1,730만 명이 심장병으로 사망하고 있어 효과적인 치료 옵션의 시급성은 그 어느 때보다 높아지고 있습니다. 고령화, 비만율의 증가, 당뇨병이나 고혈압 등의 만성 질환과 같은 요인이 이 증가의 한 요인이 되고 있습니다. 게다가 식생활의 혼란이나 약제 남용 등의 라이프 스타일의 선택도 심근 경색의 위험을 높이고 있습니다. 게다가 정확한 폐색의 검출이나 개별화 치료 어프로치를 위한 혁신적인 방법이 기대되는 기술의 진보도 시장을 뒷받침하고 있습니다. 효과적인 치료법이 보급됨에 따라 심근경색 치료 시장은 확대되어 이해관계자들에게 유리한 기회를 가져다 줄 것으로 기대되고 있습니다.
목차
서문
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터 및 1차 데이터의 방법
시장 규모 예측
시장의 전제조건 및 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학 및 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인 및 기회
성장 억제요인 및 과제
Porter's Five Forces 분석
주요 시장 인사이트
중요성공요인
경쟁도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제지표
밸류체인 분석
가격 분석
기술 분석
규제 분석
특허 분석
사례 연구
세계의 심근경색(MI) 치료제 시장 규모 : 치료 유형별 및 CAGR(2025-2032년)
시장 개요
혈전 용해
스트렙토키나아제
재조합 조직 플라스미노겐 활성화 인자(rtPA)
1차 경피적 관상동맥 인터벤션(PCI)
풍선 혈관 성형술
스텐트 유치술(약제 용출 스텐트 베어 메탈 스텐트)
관상 동맥 우회 이식(CABG)
약물(수술 또는 개입 요법 전후에 사용됨)
기타 새로운 치료법
세계의 심근경색(MI) 치료제 시장 규모 : 약제 클래스별 및 CAGR(2025-2032년)
시장 개요
항혈소판약
항응고제
베타 차단제
스타틴(콜레스테롤 저하제)
아토르바스타틴
기타
세계의 심근경색(MI) 치료제 시장 규모 : 투여 경로별 및 CAGR(2025-2032년)
시장 개요
경구
정제
캡슐
주사
정맥내(IV)
피하(SC)
경피
패치
세계의 심근경색(MI) 치료제 시장 규모 : 최종 사용자별 및 CAGR(2025-2032년)
시장 개요
병원
전문 클리닉
외래수술센터(ASC)
재택 치료
세계의 심근경색(MI) 치료제 시장 규모 및 CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 정보
상위 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 프로파일
제품 포트폴리오 분석
부문별 점유율 분석
수익의 전년대비 비교(2022-2024년)
주요 기업 프로파일
AstraZeneca Plc(UK)
Boehringer Ingelheim International GmbH(Germany)
Eli Lilly and Company(US)
Amgen(US)
Novartis AG(Switzerland)
Idorsia Pharmaceuticals Ltd.(Switzerland)
Faraday Pharmaceuticals(US)
Immediate Therapeutics(US)
Mitsubishi Chemical Group(Japan)
Kancera(Sweden)
Bayer AG(Germany)
Recardio(US)
Mesoblast Ltd.(Australia)
Athera BIoTechnologies AB(Sweden)
Bristol Myers Squibb Co.(US)
CeleCor Therapeutics(US)
CHIESI Farmaceutici SpA(Italy)
CSL Ltd.(Australia)
Ever Supreme Bio Technology(Taiwan)
결론 및 권장사항
AJY
영문 목차
영문목차
Global Myocardial Infarction (MI) Therapeutics Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.73 billion in 2024 to USD 32.32 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).
The Myocardial Infarction (MI) Therapeutics Market is poised for significant growth, primarily driven by the rising incidence of coronary artery disease, the leading cause of heart attacks. With approximately 17.3 million global fatalities attributed to heart disease annually, the urgency for effective treatment options has never been higher. Factors such as an aging population, increasing rates of obesity, and chronic conditions like diabetes and hypertension are contributing to this uptick. Additionally, lifestyle choices, including poor diet and substance abuse, are escalating myocardial infarction risk. The market is further bolstered by advancements in technology, promising innovative methods for precise blockage detection and personalized treatment approaches. As effective therapies gain traction, the MI treatment market is expected to expand, presenting lucrative opportunities for stakeholders.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Myocardial Infarction (MI) Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Myocardial Infarction (MI) Therapeutics Market Segmental Analysis
Global Myocardial Infarction (MI) Therapeutics Market is segmented by Therapy Type, Drug Class, Route of Administration, End-User and region. Based on Therapy Type, the market is segmented into Thrombolysis, Primary Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications (used before or after surgery or intervention therapy) and Other Emerging Therapies. Based on Drug Class, the market is segmented into Antiplatelet Agents, Anticoagulants, Beta-Blockers, Statins (Cholesterol-Lowering Drugs), Atorvastatin and Others. Based on Route of Administration, the market is segmented into Oral, Tablets, Capsules, Injectable, Intravenous (IV), Subcutaneous (SC), Transdermal and Patches. Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs) and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Myocardial Infarction (MI) Therapeutics Market
The global Myocardial Infarction (MI) Therapeutics Market is expected to experience significant growth due to the increasing prevalence of heart attacks worldwide. Key factors contributing to this growth include the rising rates of coronary artery disease and lifestyle changes, which are leading to more cases of MI. Over the upcoming years, a surge in hypertension, obesity, and smoking prevalence is likely to further stimulate demand for myocardial infarction therapies. As healthcare systems adapt to address these challenges, the market is anticipated to expand, reflecting the growing need for effective treatments and interventions to manage this critical health issue.
Restraints in the Global Myocardial Infarction (MI) Therapeutics Market
The global Myocardial Infarction (MI) Therapeutics Market faces several significant constraints that may impede its growth in the coming years. Chief among these are the escalating costs associated with research and development, alongside limitations in R&D activities. Additionally, rising overall healthcare expenditures, stringent regulatory requirements, and the substantial financial investments needed for clinical trials further compound these challenges. These factors collectively create a challenging environment for companies aiming to innovate and develop effective treatments for myocardial infarction, potentially stunting market expansion and advancements in therapeutic options for patients.
Market Trends of the Global Myocardial Infarction (MI) Therapeutics Market
The Global Myocardial Infarction (MI) Therapeutics Market is increasingly influenced by the integration of nanoparticle technology, facilitating targeted drug delivery and advanced imaging techniques for cardiovascular diseases. Recent innovations in nanoparticle design and functionality are enhancing preclinical research, enabling efficient therapeutic mechanisms that address critical challenges such as low bioavailability and bioimaging inefficiencies. By focusing on specific actions against inflammation, fibrogenesis, and promoting angiogenesis, the development of nanocarrier systems is poised to revolutionize MI treatment. This trend reflects a significant shift toward precision medicine, presenting opportunities for more effective solutions in MI diagnostics and therapeutics, thus shaping the future landscape of cardiovascular care.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Regulatory Analysis
Patent Analysis
Case Studies
Global Myocardial Infarction (MI) Therapeutics Market Size by Therapy Type & CAGR (2025-2032)
Market Overview
Thrombolysis
Streptokinase
Recombinant Tissue Plasminogen Activator (rtPA)
Primary Percutaneous Coronary Intervention (PCI)
Balloon Angioplasty
Stenting (Drug-Eluting Stents, Bare-Metal Stents)
Coronary Artery Bypass Grafting (CABG)
Medications (used before or after surgery or intervention therapy)
Other Emerging Therapies
Global Myocardial Infarction (MI) Therapeutics Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Antiplatelet Agents
Anticoagulants
Beta-Blockers
Statins (Cholesterol-Lowering Drugs)
Atorvastatin
Others
Global Myocardial Infarction (MI) Therapeutics Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Tablets
Capsules
Injectable
Intravenous (IV)
Subcutaneous (SC)
Transdermal
Patches
Global Myocardial Infarction (MI) Therapeutics Market Size by End-User & CAGR (2025-2032)
Market Overview
Hospitals
Specialty Clinics
Ambulatory Surgical Centers (ASCs)
Homecare Settings
Global Myocardial Infarction (MI) Therapeutics Market Size & CAGR (2025-2032)
North America (Therapy Type, Drug Class, Route of Administration, End-User)
US
Canada
Europe (Therapy Type, Drug Class, Route of Administration, End-User)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Therapy Type, Drug Class, Route of Administration, End-User)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Therapy Type, Drug Class, Route of Administration, End-User)
Brazil
Rest of Latin America
Middle East & Africa (Therapy Type, Drug Class, Route of Administration, End-User)
